FDA 召回 580K 吡唑嗪瓶，原因是与癌症相关的杂质;没有疾病报告。 FDA recalls 580K prazosin bottles over cancer-linked impurity; no illnesses reported.

美国食品和药物管理局召回了580,000多瓶帕拉佐辛,这是一种血压药物,其原因是N-硝基索帕拉佐辛杂质C(一种与动物研究中的癌症有关的硝酸胺)污染。 The U.S. FDA has recalled over 580,000 bottles of prazosin, a blood pressure medication, due to contamination with N-nitroso prazosin impurity C, a nitrosamine linked to cancer in animal studies. 从全国分布的特定批量中召回1毫克、2毫克和5毫克胶囊,无疾病报告。 The recall affects 1 mg, 2 mg, and 5 mg capsules from specific lots distributed nationwide, with no illnesses reported. 归为第二类,严重损害的风险较低,但超过安全限度的长期接触可能会增加癌症风险。 Classified as a Class II recall, the risk of serious harm is low, but long-term exposure above safety limits may increase cancer risk. 病人不应突然停止服药,因为这可能导致高血压复发或其他并发症。 Patients should not stop taking the medication abruptly, as this could lead to rebound hypertension or other complications. 建议他们检查药品批量数, 咨询医疗服务提供者, 并讨论安全替代方法。 They are advised to check their medication’s lot number, consult their healthcare provider, and discuss safe alternatives. 此次回顾是在对其他药物采取类似行动之后进行的,突出了对药物中硝酸胺污染的持续关切。 The recall follows similar actions on other drugs, highlighting ongoing concerns about nitrosamine contamination in pharmaceuticals.